- Stocks
- Pharma & Healthcare
- Fervent Synergi
Fervent Synergi share price
NSE: FERVENTSYNPharma & HealthcareFood Distribution
Fervent Synergi at a glance
With a market capitalisation of ₹68 Cr, it ranks 2893rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Food Distribution.
Its return on equity was 6.1% in FY25. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹1 Cr (+8.8% year on year) and net profit ₹0 Cr (−47.4%), on a standalone basis. Promoters held 74.75% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹68 CrRank 2893 on NSE
- Price to book
- 1.99×FY25
- EPS (TTM)
- ₹0.73to Q1 FY27
- ROE
- 6.1%FY25
- ROCE
- 6.1%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 9.1%FY25
- Book value / share
- ₹11.12FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Fervent Synergi quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹26 Cr | ₹5 Cr | ₹1 Cr | ₹1 Cr | ₹10 Cr | ₹5 Cr | ₹1 Cr |
| Revenue YoY | +21.9% | +198.2% | −63.6% | +100.0% | +74.4% | −62.9% | −3.7% | +8.8% |
| Net profit | ₹0 Cr | ₹2 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹1 Cr | ₹0 Cr |
| Net profit YoY | −55.6% | +535.1% | — | +442.9% | +975.0% | −8.9% | +74.0% | −47.4% |
| Net margin | 10.3% | 8.9% | 9.3% | 55.9% | 63.2% | 21.9% | 16.7% | 27.0% |
| EPS | ₹0.01 | ₹0.54 | ₹0.11 | ₹0.08 | ₹0.09 | ₹0.43 | ₹0.17 | ₹0.04 |
Fervent Synergi financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹7 Cr | ₹2 Cr | ₹1 Cr | ₹5 Cr | ₹24 Cr | ₹32 Cr |
| Operating profit | ₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr | −₹13 Cr | ₹3 Cr |
| Net profit | ₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr | −₹13 Cr | ₹3 Cr |
| EPS (₹) | ₹0.08 | ₹0.06 | −₹0.08 | ₹0.08 | −₹4.28 | ₹0.68 |
| Cash from operations | ₹2 Cr | ₹0 Cr | −₹2 Cr | −₹0 Cr | −₹0 Cr | −₹15 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹43 Cr | ₹43 Cr | ₹43 Cr | ₹43 Cr | ₹30 Cr | ₹49 Cr |
Fervent Synergi shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 71.71% | 74.75% | 74.75% | 74.75% | 74.75% | 74.75% |
| Non-institutions | 28.28% | 25.25% | 25.25% | 25.25% | 25.25% | 25.25% |
Fervent Synergi vs peers
The listed Pharma & Healthcare companies nearest to Fervent Synergi by market capitalisation.
Ask anything about Fervent Synergi
Pivot answers on the live chart with evidence you can check, and tests strategies against FERVENTSYN's own history. Try: “Why has FERVENTSYN moved over the last three months?” · “Backtest a 50-day moving-average crossover on FERVENTSYN over five years” · “Compare FERVENTSYN with METSL on margins and valuation”
Frequently asked questions about Fervent Synergi
What is the market cap of Fervent Synergi?
Fervent Synergi's market capitalisation is ₹68 Cr (₹68 Cr) at the 22 Oct 2026 close, ranking 2893rd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Fervent Synergi?
Return on equity was 6.1% in FY25 and return on capital employed was 6.1% in FY25 (standalone figures).
Is Fervent Synergi a debt-free company?
Fervent Synergi is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Fervent Synergi's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Fervent Synergi reported revenue of ₹1 Cr, +8.8% year on year, and net profit of ₹0 Cr, −47.4% year on year.
What is the shareholding pattern of Fervent Synergi?
As of 30 Jun 2026: promoters 74.75%, non-institutions 25.25%.
Who are Fervent Synergi's competitors?
The listed Pharma & Healthcare companies closest to Fervent Synergi by market cap are Maestros Elect, Bharat Immuno, Source Natural, Asston Pharma, Sunil Health and Samrat Pharma.
Is Fervent Synergi a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Fervent Synergi's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FERVENTSYN against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with F · all NSE stocks · this page as text